TOTuba Ozdemir-Sanci

Tuba Ozdemir-Sanci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tuba Ozdemir-Sanci has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tomentosin Potentiates Cisplatin-Induced Apoptosis and Modulates Proteostasis-Related Proteins in A549 Lung Cancer Cells

    by Hilal Nakkas, Beyza Ecem Oz-Bedir, Emine Terzi, Tuba Ozdemir-Sanci, Monica Angela Neblea, Tuba Aydin

    Lung cancer remains a leading cause of cancer-related mortality worldwide, highlighting the need for improved therapeutic strategies and adjunct treatment approaches. In this study, we investigated the anticancer effects of tomentosin in A549 cells and evaluated the cellular response to its combined exposure with cisplatin. Cell viability was assessed using the WST-1 assay in A549 and BEAS-2B cells. Apoptosis was evaluated by Annexin V-FITC/PI staining, cell-cycle distribution by flow cytometry, and caspase-3/7 activity by a flow cytometric assay. In addition, intracellular levels of the proteostasis-related proteins p97/VCP, SVIP, and p62/SQSTM1 were quantified by flow cytometry. Tomentosin reduced A549 cell viability in a dose- and time-dependent manner, with a 24 h IC50 value of 24.46 ± 1.61 µM, while producing a comparatively lower cytotoxic response in BEAS-2B cells. Tomentosin increased apoptotic cell populations and altered cell-cycle distribution. Combined exposure to tomentosin and cisplatin resulted in an early apoptotic population of 72.58 ± 0.47%, compared with 2.06 ± 0.11% in control cells, and was associated with greater caspase-3/7 activity than either treatment alone. Tomentosin and/or cisplatin also produced significant alterations in p97/VCP, SVIP, and p62 levels. These findings indicate that tomentosin exerts antiproliferative and pro-apoptotic effects in A549 cells and that combined exposure with cisplatin is associated with a greater biological response under the investigated in vitro conditions. The accompanying changes in p97/VCP, SVIP, and p62 suggest modulation of proteostasis-associated cellular responses; however, their functional contribution to the treatment response remains to be established.

  • Open Access

    Protective Effects of Luteolin Against Cisplatin‐Induced Hepatic and Renal Toxicity: Biochemical and Cellular Evidence

    by Özge Temiz, Suna Kizilyildirim, Tuba Ozdemir‐Sanci, Emine Terzi, Beyza Ecem Oz‐Bedir, Mehmet Akyuz, Hikmet Y. Cogun, Ferit Kargin, Tuba Aydin, Ahmet Cakir

    Cisplatin is a widely used chemotherapeutic agent; however, its clinical utility is frequently limited by dose‐dependent adverse effects, particularly hepatotoxicity and nephrotoxicity. Luteolin, a naturally occurring flavonoid abundant in various medicinal plants, exhibits well‐documented antioxidant and anticancer activities. This study investigated whether Luteolin isolated from Pistacia terebinthus fruits could attenuate Cisplatin‐induced organ toxicity while enhancing its antiproliferative effects. For the in vivo experiments, 48 male Swiss albino mice (9–10 weeks old, 26–30 g) were randomly assigned to eight groups ( n = 6/group): control, Cisplatin, Luteolin (25, 50, or 100 mg/kg), and Cisplatin plus Luteolin (25, 50, or 100 mg/kg). Cisplatin (10 mg/kg/day, intraperitoneally) and/or Luteolin (25–100 mg/kg/day, orally) were administered for 14 consecutive days. Serum biochemical parameters, oxidative stress markers, antioxidant enzyme activities, and tissue injury‐related biomarkers were evaluated in liver and kidney tissues. Cisplatin administration significantly increased serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and glucose levels, whereas co‐treatment with Luteolin markedly attenuated these alterations in a dose‐dependent manner. In addition, Luteolin restored Cisplatin‐induced disturbances in oxidative stress and antioxidant defense markers, including malondialdehyde (MDA), 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG), HSP70 levels, superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), and glutathione S‐transferase (GST) activities in liver and kidney tissues. To support the in vivo findings, in vitro antiproliferative assays were performed using Saos‐2 osteosarcoma, HTB‐9 bladder cancer, A549 lung cancer, and BEAS‐2B normal epithelial cell lines. Cells were treated with Luteolin (5–200 µM) alone or in combination with Cisplatin IC50 concentrations for 24–48 h, and cell viability was assessed using the WST‐1 assay. Co‐treatment with Luteolin significantly enhanced Cisplatin‐induced growth inhibition in cancer cells while exerting limited cytotoxicity in normal cells. Luteolin alone also demonstrated concentration‐dependent antiproliferative activity. In conclusion, Luteolin exerted marked hepatorenal protective effects and enhanced the antiproliferative activity of Cisplatin in experimental models. These findings suggest that Luteolin may represent a promising adjunctive candidate for reducing Cisplatin‐associated toxicity while improving therapeutic responsiveness.

  • Design, Synthesis, and In Vitro Biological Assessment of Novel Benzimidazole and Hydrazone Derivatives Against Pancreatic Cancer and Melanoma Cells

    by Beyza Ecem Oz Bedir, Tuba Ozdemir Sanci, Emine Terzi, Elif Ercan, Nour El‐Huda Daoud, Ulviye Acar Çevik

    In this study, novel Benzimidazole‐Hydrazone derivatives ( 5A–5J ) were synthesized and evaluated for their in vitro anticancer activities against Panc‐1, SK‐MEL‐30, HeLa, and BEAS‐2B cell lines. WST‐1 cytotoxicity assays revealed that compound 5A displayed notable potency in SK‐MEL‐30 cells (IC 50 = 23.25 ± 1.40 μM), whereas compound 5H exhibited significant cytotoxicity in Panc‐1 cells (IC 50 = 27.6 ± 1.1 μM), with minimal effects on BEAS‐2B cells (> 200 μM), suggesting a favorable in vitro safety profile under the tested conditions. Flow cytometric analyses demonstrated that 5A and 5H induced apoptosis and enhanced the apoptotic response when combined with Cisplatin, increasing apoptotic rates up to 80% in SK‐MEL‐30 and 90% in Panc‐1 cells, respectively. Cell cycle analysis revealed that compound 5A induced G1 arrest in SK‐MEL‐30 cells, while compound 5H caused G2/M arrest in Panc‐1 cells. Wound healing assays further confirmed the antimigratory potential of both compounds, alone and in combination with Cisplatin. In silico ADMET profiling provided preliminary insights into the pharmacokinetic properties of compounds 5A and 5H , indicating generally acceptable drug‐likeness parameters within the limitations of computational prediction. Molecular docking analyses suggested potential interactions with the caspase‐3 active site; however, these findings should be interpreted as supportive computational observations and do not provide direct evidence of a specific molecular mechanism underlying the observed apoptotic effects. These findings indicated that compounds 5A and 5H exhibited notable in vitro anticancer activity and may serve as potential candidates for further investigation.

  • Comparative Cytotoxic and Anti-Migratory Effects of Cisplatin and Theobromine in Human Bladder Cancer Cells

    by Beyza Ecem Oz Bedir, Tuba Özdemir Sancı, Emine Terzi

    Background: Bladder cancer continues to pose a major global health challenge, as therapeutic options are often con-strained by treatment-related toxicity and the emergence of resistance to chemotherapy. We investigated the cytotoxic and anti-migratory effects of Theobromine, a natural alkaloid, in HT-1376 bladder cancer cells and compared its activity with Cisplatin, a standard chemotherapeutic agent.Methods: Cellular metabolic activity was quantified via the WST-1 colorimetric assay, while migratory capacity was examined using wound healing assay.Results: Treatment with Theobromine induced a time- and dose-responsive decrease in HT-1376 cell viability, with IC₅₀ values of 134.3 µM after 24 h, while Cisplatin exhibited stronger cytotoxicity with an IC₅₀ value of 35.97 µM. Both agents significantly inhibited cell migration, with the combination of Theobromine and Cisplatin showing the most pronounced anti-migratory effect. The wound healing assay revealed that the combination treatment significantly reduced wound closure compared to either compound alone (p < 0.0001), while Theobromine alone resulted in moderate inhibition (p = 0.0001). Importantly, no significant cytotoxicity was observed in NIH/3T3 fibroblast cells at concentrations up to 200 µM for Theobromine and 50 µM for Cisplatin, indicating differential sensitivity between bladder cancer cells and normal fibroblast cells.Conclusion: These findings suggest that Theobromine may act as a potential adjunct to Cisplatin-based therapy in blad-der cancer cells. Further experimental studies are required to elucidate the underlying molecular mechanisms responsible for the enhanced inhibitory effect and to evaluate the efficacy of this combined treatment in animal models.

  • Open Access

    Selective cytotoxicity of Arctium extracts in pancreatic, bladder, and colorectal cancer cell lines: A comparative dose-response study

    by Tuba Özdemir Sancı, Beyza Ecem Oz Bedir, Emine Terzi, Benan Kalaycı, Tuba Aydın, Fevzi Özgökçe, Ahmet Çakır

    Gastrointestinal and urinary tract cancers, including colorectal, pancreatic, and bladder malignancies, represent a major global health burden due to their high mortality and therapeutic resistance. In light of the limitations of current treatment strategies, plant-derived compounds with multitargeted actions have emerged as promising alternatives. This study aimed to evaluate the cytotoxic effects of methanol and dichloromethane:methanol (1:1) extracts of Arctium minus subsp. pubens, A. minus subsp. minus, and A. tomentosum var. glabrum on three human cancer cell lines: HTB-9 (bladder), DLD-1 (colorectal), and PANC-1 (pancreatic). Extracts were prepared from aerial parts of plants using two solvents of differing polarity. Cell viability was determined after 24 and 48 hours using the WST-1 assay. IC₅₀ values were calculated, and statistical comparisons were performed. All extracts exhibited dose-dependent cytotoxicity. The methanol extract of A. tomentosum showed the strongest effect in HTB-9 cells, while A. minus subsp. pubens demonstrated potent activity against DLD-1 and PANC-1 cells. The findings highlight the selective cytotoxic potential of Arctium species, especially A. minus subsp. pubens and A. tomentosum, which may serve as valuable candidates for further phytochemical and mechanistic anticancer studies.

  • Thiazole‐ and 1,3,4‐Thiadiazole‐Based Hybrids: Synthesis and In Vitro Cytotoxicity Against Human Cancer Cell Lines

    by Emine Terzi, Tuba Ozdemir Sanci, Beyza Ecem Oz Bedir, Elif Ercan, Emine Rana Bağcı, Ulviye Acar Çevik, Ecem Kaya Sezginer

    Problems such as high toxicity, low selectivity, and drug resistance encountered in cancer treatment increase the need for more effective and safe anticancer agents. In this study, the anticancer effects of new compounds consisting of thiazole and 1,3,4‐thiadiazole derivatives were investigated. Compound 6e , which showed the strongest cytotoxic effect, was evaluated in detail in human bladder (HTB‐9) and lung (A549) cancer cells. According to the WST‐1 test results, the IC 50 value of compound 6e was determined as 38.9 μM for HTB‐9 cells and 82.86 μM for A549 cells. As a result of Annexin V‐FITC/PI double staining and flow cytometry analysis, it was determined that compound 6e application significantly increased the apoptotic cell rates in both HTB‐9 and A549 cells. It was observed that it significantly induced early apoptosis in HTB‐9 cells and late apoptosis in A549 cells ( p < 0.0001). Caspase‐3/7 activity was significantly increased in HTB‐9 cells after compound 6e application compared to the control group and similarly increased in A549 cells ( p < 0.0001). In cell cycle analyses, compound 6e caused cell cycle arrest in the G2/M phase in HTB‐9 and A549 cells. In the wound healing test, the migration speed in HTB‐9 and A549 cells treated with compound 6e after 24 h was significantly decreased ( p < 0.0001). Molecular docking revealed strong binding to caspase‐3 (PDB ID: 1NMQ, score: −8.2 kcal/mol), identifying key interactions that mechanistically support its pro‐apoptotic effects. In addition, the low cytotoxicity of compound 6e in healthy BEAS‐2B cells suggests that it has a selective anticancer effect.


  • Open Access

    Comparative Cytotoxic Effects of Silver Nanoparticles Synthesized from Humulus lupulus, Inula viscosa, and Olea europaea on Saos-2 and MCF-7 Cells

    by Tuba Ozdemir-Sanci, Busranur Ozalper, Tuba Aydin, Mustafa Gungormus

    Recent advances in green nanotechnology have enabled the development of plant-mediated silver nanoparticles (AgNPs) as promising anti-cancer agents. This study characterizes AgNPs biosynthesized using aqueous extracts of three medicinal plants—Humulus lupulus (hops), Inula viscosa, and Olea europaea (olive)—and evaluates their cytotoxic effects against Saos-2 osteosarcoma and MCF-7 breast cancer cell lines. Ultraviolet–Visible Spectroscopy (UV–Vis) confirmed nanoparticle formation through characteristic surface plasmon resonance (SPR) peaks (400–420 nm), while scanning electron microscopy revealed spherical particles (30–70 nm) with moderate aggregation. Additionally, X-ray diffraction (XRD) analysis confirmed the crystalline nature of the synthesized silver nanoparticles. The viability assay demonstrated significant dose- and time-dependent cytotoxicity, with I. viscosa-AgNPs showing particularly strong effects. Comparative analysis revealed plant-synthesized AgNPs exhibited enhanced biocompatibility and selective toxicity compared to chemically synthesized counterparts. The green synthesis approach employed in this study not only eliminates toxic chemical reductants but also enhances therapeutic potential through synergistic phytochemical-nanoparticle interactions. These results position plant-mediated AgNPs as a sustainable and effective alternative for targeting aggressive cancers like osteosarcoma and hormone-resistant breast cancer. The study highlights the importance of integrating traditional medicinal knowledge with modern nanotechnology for developing novel cancer therapeutics.


  • Open Access

    Effect of naringin and cisplatin combination on cell viability and cell death in bladder cancer cells

    by Tuba Ozdemir-Sanci, Ebru Alimogullari

    Bladder cancer is a prevalent malignancy characterized by high recurrence rates and limited therapeutic options, particularly due to resistance and toxicity associated with cisplatin therapy. Bladder cancer remains a significant global health concern, and while cisplatin is a cornerstone of treatment, its efficacy is often limited by resistance and toxicity. Therefore, there is a critical need for novel agents that can enhance cisplatin's effects while mitigating its drawbacks. This study investigates the potential of naringin, a natural flavonoid, to exhibit antiproliferative and proapoptotic effects in human bladder cancer cell lines (HTB-9 and HT-1376), both as a monotherapy and in combination with cisplatin. Cytotoxicity was assessed via the MTT ((3-(4,5-dimetiltiazol-2-il)-2,5 difeniltetrazoliumbromid) assay, and apoptosis was evaluated using Annexin V/PI staining and caspase 3/7 activation assays. Results demonstrated that naringin reduced cell viability in a dose-dependent manner in both cell lines. When combined with cisplatin, naringin significantly enhanced the antiproliferative and pro-apoptotic effects compared to either treatment alone. Caspase 3/7 activity was markedly elevated in the combination groups, indicating an amplified apoptotic response. These findings suggest that naringin can potentiate cisplatin’s efficacy and could serve as a promising adjunctive therapy in bladder cancer treatment. Further studies are warranted to explore the underlying mechanisms and potential clinical applications of naringin in enhancing cisplatin-based chemotherapy.


  • Open Access

    The dynamic interaction of pediatric ALL cells and MSCs: influencing leukemic cell survival and modulating MSC β-catenin expression

    by Tuba Ozdemir-Sanci, Ilkay Piskin, Yasin Köksal, Sevil Cayli, Namik Y. Ozbek, H. Meltem Ozguner

    Bone marrow mesenchymal stromal cells (BM-MSCs) are integral components of the bone marrow microenvironment, playing a crucial role in supporting hematopoiesis. Recent studies have investigated the potential involvement of BM-MSCs in the pathophysiology of acute lymphoblastic leukemia (ALL). However, the exact contribution of BM-MSCs to leukemia progression remains unclear because of conflicting findings and limited characterization. In this study, we compared BM-MSCs derived from pediatric ALL patients with those from matched healthy donors (HDs). Our results indicate that while both ALL-MSCs and HD-MSCs meet the criteria established by the International Society for Cellular Therapy, they exhibit significant differences in proliferation and differentiation capacity. ALL-MSCs displayed markedly lower proliferation rates and reduced osteogenic/adipogenic differentiation potential compared to HD-MSCs. Furthermore, co-culture experiments revealed that MSCs enhance the survival of leukemic blasts through both soluble factors and direct cell-cell interactions, underscoring their anti-apoptotic properties. Importantly, our findings demonstrate that interactions with leukemic cells activate the Wnt/β-catenin signaling pathway in MSCs, suggesting a potential target for therapeutic intervention. Overall, this study enhances our understanding of the role of BM-MSCs in leukemia and highlights β-catenin as a promising target for future therapies.